公开(公告)号：US20200165236A1

公开(公告)日：2020-05-28

申请号：US16633684

申请日：2018-07-25

申请人： Yuhan Corporation

发明人： Sang-Ho OH ,  Ja-Heouk KHOO ,  Jong-Chul LIM ,  Seong-Ran LEE ,  Hyun JU ,  Woo-Seob SHIN ,  Dae-Gyu PARK ,  Su-Min PARK ,  Yoon-Ah HWANG

IPC分类号： C07D413/14

摘要： The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.

公开(公告)号：US20190153055A1

公开(公告)日：2019-05-23

申请号：US16097572

申请日：2017-04-19

申请人： YUHAN CORPORATION

发明人： Su Youn Nam ,  Jong Gyun Kim ,  Byung Hyun Choi ,  June Hyung Lee ,  Ju Young Park ,  Jun Kyung Lee ,  Na Rae Lee ,  Ki Hong Kim ,  Seul Gi Kim ,  Se Woong Oh ,  Seung Yub Shin ,  Ho Woong Kang ,  Su Jin Ahn ,  Soo Yong Chung

IPC分类号： C07K14/52 ,  A61P35/00

摘要： Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3α or CCL3β is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3α or CCL3β in the CCL3 variant.

公开(公告)号：US20190142809A1

公开(公告)日：2019-05-16

申请号：US16315814

申请日：2017-07-06

申请人： Yuhan Corporation

发明人： Se-Woong Oh ,  Youn Hur ,  Jin-Hwi Park ,  Jae-Eun Joo ,  Ho-Woong Kang ,  Hyok-Jun Cho ,  Eui-Chul Lee ,  Chan-Sun Park ,  Dong-Hyun Kim ,  Jong-Gyun Kim ,  Su-Youn Nam

IPC分类号： A61K31/428 ,  A61P35/04

CPC分类号： A61K31/428 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61P35/04 ,  C07D277/82

摘要： The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

公开(公告)号：US20180147150A1

公开(公告)日：2018-05-31

申请号：US15882390

申请日：2018-01-29

申请人： YUHAN CORPORATION

发明人： Jeong-Hoon WOO ,  Woon-Sook NA ,  Yang-Soo JEONG ,  Chang-Keun HYUN ,  Yoong-Sik PARK

IPC分类号： A61K9/20 ,  A61K31/197 ,  A61K9/00 ,  A61P25/08

CPC分类号： A61K9/2031 ,  A61K9/0002 ,  A61K9/0065 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2095 ,  A61K31/197 ,  A61P25/08

摘要： Provided is a sustained release tablet having two-phase release-controlling system, which consists of a first release-controlling phase including pregabalin or its salt and hydroxypropyl methylcellulose; and a second release-controlling phase including polyethylene oxide as a swelling polymer, the first release-controlling phase being homogeneously dispersed in the second release-controlling phase.

公开(公告)号：US20130116439A1

公开(公告)日：2013-05-09

申请号：US13726932

申请日：2012-12-26

申请人： YUHAN CORPORATION

发明人： Chun-Ho Lee ,  Ja-Heouk Khoo ,  Kyoung-Chan Kwon ,  Hyun Ju

IPC分类号： C07D401/04

CPC分类号： C07D401/04 ,  C07C67/31 ,  C07C67/46 ,  C07C69/612

摘要： The present invention relates to a process for preparing 2-methyl-2′-phenylpropionic acid derivatives showing antihistamine activity in more simplified way, intermediate compounds and their preparation processes used therefore. According to the present invention, pharmaceutically useful 2-methyl-2′-phenylpropionic acid derivatives can be prepared with high yield and purity on industrial scale.

摘要翻译： 本发明涉及以更简化的方式制备显示出抗组胺活性的2-甲基-2'-苯基丙酸衍生物的方法，因此中间体化合物及其制备方法。 根据本发明，可以以工业规模高产率和纯度制备药学上可用的2-甲基-2'-苯基丙酸衍生物。

公开(公告)号：US20240279203A1

公开(公告)日：2024-08-22

申请号：US18618379

申请日：2024-03-27

申请人： Yuhan Corporation

发明人： Sang Ho OH ,  Jong Gyun KIM ,  Se-Woong OH ,  Tae Dong HAN ,  Soo Yong CHUNG ,  Seong Ran LEE ,  Kyeong Bae KIM ,  Young Sung LEE ,  Woo Seob SHIN ,  Hyun JU ,  Jeong Ki KANG ,  Su Min PARK ,  Dong Kyun KIM

IPC分类号： C07D403/04 ,  C07C303/22 ,  C07C309/04

CPC分类号： C07D403/04 ,  C07C303/22 ,  C07C309/04 ,  C07B2200/13

摘要： The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.

公开(公告)号：US20240190959A1

公开(公告)日：2024-06-13

申请号：US18412102

申请日：2024-01-12

申请人： Yuhan Corporation

发明人： Heyue Zhou

IPC分类号： C07K16/28 ,  C07K16/30

CPC分类号： C07K16/2803 ,  C07K16/2827 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/51 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92

摘要： There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.

公开(公告)号：US20240180917A1

公开(公告)日：2024-06-06

申请号：US18453743

申请日：2023-08-22

申请人： Janssen Biotech, Inc. ,  Yuhan Corporation

发明人： Seonmi Kang ,  Sewoong Oh

IPC分类号： A61K31/5377 ,  A61P35/00 ,  A61P35/04

CPC分类号： A61K31/5377 ,  A61P35/00 ,  A61P35/04

摘要： The present invention relates to therapies with 3rd generation EGFR tyrosine kinase inhibitors. Embodiments of the invention relate to the administration of lazertinib to patients diagnosed with non-small cell lung cancer (NSCLC).

公开(公告)号：US11981659B2

公开(公告)日：2024-05-14

申请号：US17697655

申请日：2022-03-17

申请人： Yuhan Corporation

发明人： Sang Ho Oh ,  Jong Gyun Kim ,  Se-Woong Oh ,  Tae Dong Han ,  Soo Yong Chung ,  Seong Ran Lee ,  Kyeong Bae Kim ,  Young Sung Lee ,  Woo Seob Shin ,  Hyun Ju ,  Jeong Ki Kang ,  Su Min Park ,  Dong Kyun Kim

IPC分类号： C07D403/04 ,  C07C303/22 ,  C07C309/04

CPC分类号： C07D403/04 ,  C07C303/22 ,  C07C309/04 ,  C07B2200/13

摘要： The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.

公开(公告)号：US20230090406A1

公开(公告)日：2023-03-23

申请号：US17822445

申请日：2022-08-26

申请人： YUHAN CORPORATION ,  JANSSEN BIOTECH, INC.

发明人： Hyunjoo LEE ,  Su Bin CHOI ,  Misong KIM ,  Young Ae YOON ,  Kwan Hoon HYUN ,  Jae Young SIM

IPC分类号： C07D401/14 ,  C07D413/14

摘要： Provided are 6-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.